Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia

Leuk Res. 2023 Jul:130:107313. doi: 10.1016/j.leukres.2023.107313. Epub 2023 May 16.

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
² Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan. Electronic address: knagafuji@med.kurume-u.ac.jp.

PMID: 37207502
DOI: 10.1016/j.leukres.2023.107313

No abstract available

Keywords: Acute myeloid leukemia; Azacytidine; FLT3 inhibitor; Measurable residual disease; Nucleophosmin; Venetoclax.

Publication types

Letter

MeSH terms

Azacitidine / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Mutation
Nuclear Proteins* / genetics
Prognosis
fms-Like Tyrosine Kinase 3 / genetics

Substances

venetoclax
Nuclear Proteins
Bridged Bicyclo Compounds, Heterocyclic
Azacitidine
fms-Like Tyrosine Kinase 3
FLT3 protein, human